FIELD: medicine.
SUBSTANCE: invention refers to application of enterovirus in preparing a pharmaceutical composition for prevention or treatment of the diseases associated with IgE-mediated allergic sensitisation and related diseases with using an enteroviral vaccine in which enterovirus does not contain an exogenous nucleotide sequence integrated into a viral genome and coding an allergen causing said allergic sensitisation, and also to a method for prevention or treatment of said diseases.
EFFECT: effective products for treating said diseases.
10 cl, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING ATTENUATED Streptococcus pneumoniae STRAINS, AND ITS APPLICATION | 2018 |
|
RU2772131C2 |
| METHOD FOR ASSESSMENT OF EFFICIENCY OF ALLERGEN-SPECIFIC IMMUNOTHERAPY IN ALLERGIC RHINITIS | 2019 |
|
RU2700788C1 |
| METHOD FOR PREVENTING AND TREATING BRONCHIAL ASTHMA, COMPLICATING RESPIRATORY VIRAL INFECTIONS AND OTHER RESPIRATORY INFLAMMATORY DISEASES | 2012 |
|
RU2526146C2 |
| COMPOSITION FOR ATOPIC DERMATITIS THERAPY BASED ON FULLEREN | 2016 |
|
RU2641041C1 |
| PROBIOTIC STRAIN OF Bifidobacterium longum, COMPOSITION CONTAINING SUCH STRAIN AND USE THEREOF | 2008 |
|
RU2473681C2 |
| NUTRITIONAL COMPOSITION CONTAINING STRAINS BIFIDOBACTERIUM LONGUM AND RELIEVING SYMPTOMS OF FOOD ALLERGY, ESPECIALLY IN INFANTS AND CHILDREN | 2010 |
|
RU2539514C2 |
| METHOD FOR ALLERGIC BRONCHIAL ASTHMA TREATMENT, BASED ON CYTOKINES IL-4 AND IL-13 GENES EXPRESSION INHIBITION USING SIRNA MOLECULES | 2016 |
|
RU2615463C1 |
| METHOD FOR PREPARING FOR MANTOUX TEST WITH 2 TE PPD-L IN CHILDREN WITH BURDENED ALLERGICAL HISTORY | 2013 |
|
RU2549444C1 |
| MUCOSAL INDUCTION OF ANTIGEN TOLERANCE | 2006 |
|
RU2420569C2 |
| SEMI-SOFT C-CLASS IMMUNOSTIMULATORY OLIGONUCLEOTIDES | 2005 |
|
RU2393223C2 |
